Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Mitiglinide: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 447615903 of page Mitiglinide for the Chem/Drugbox validation project (updated: 'ChEMBL', 'CAS_number'). |
Citation bot (talk | contribs) Add: s2cid. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar |
||
| Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Mitiglinide|oldid=447615903}} 447615903] of page [[Mitiglinide]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
| ⚫ | |||
| Watchedfields = changed |
|||
| IUPAC_name = (2''S'')-2-benzyl-4-[(3a''R'',7a''S'')-octahydro-2''H''-isoindol- 2-yl]-4-oxobutanoic acid |
|||
| ⚫ | |||
| IUPAC_name = (−)-(2''S'',3a,7a-''cis'')-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid |
|||
| image = Mitiglinide.svg |
| image = Mitiglinide.svg |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = Glufast |
||
| Drugs.com = {{drugs.com|international|mitiglinide}} |
| Drugs.com = {{drugs.com|international|mitiglinide}} |
||
| routes_of_administration = |
| routes_of_administration = [[Oral administration|By mouth]] ([[Tablet (pharmacy)|tablets]]) |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|changed|??}} |
|||
| CAS_number = <!-- blanked - oldvalue: 207844-01-7 --> |
|||
| CAS_number = 145375-43-5 |
|||
| ATC_prefix = A10 |
| ATC_prefix = A10 |
||
| ATC_suffix = BX08 |
| ATC_suffix = BX08 |
||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|||
| ChEMBL = 471498 |
| ChEMBL = 471498 |
||
| PubChem = 121891 |
| PubChem = 121891 |
||
| Line 27: | Line 31: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=19 | H=25 | N=1 | O=3 |
| C=19 | H=25 | N=1 | O=3 |
||
| molecular_weight = 315.41 g/mol |
|||
| smiles = O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3 |
| smiles = O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3 |
||
| InChI = 1/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 |
|||
| InChIKey = WPGGHFDDFPHPOB-BBWFWOEEBF |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 |
| StdInChI = 1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 |
||
| Line 36: | Line 37: | ||
| StdInChIKey = WPGGHFDDFPHPOB-BBWFWOEESA-N |
| StdInChIKey = WPGGHFDDFPHPOB-BBWFWOEESA-N |
||
}} |
}} |
||
'''Mitiglinide''' ([[International nonproprietary name|INN]],<ref name="INN">{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40|url=https://www.who.int/medicines/publications/druginformation/innlists/PL78.pdf|publisher=World Health Organization|access-date=10 November 2016|page=187}}</ref> trade name '''Glufast''') is a [[drug]] for the treatment of [[Diabetes mellitus type 2|type 2 diabetes]].<ref name="pmid18803455">{{cite journal | vauthors = Malaisse WJ | title = Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients | journal = Expert Opinion on Pharmacotherapy | volume = 9 | issue = 15 | pages = 2691–8 | date = October 2008 | pmid = 18803455 | doi = 10.1517/14656566.9.15.2691 | s2cid = 73318104 }}</ref> |
|||
Mitiglinide belongs to the [[meglitinide]] (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by [[Kissei]] and [[Takeda Pharmaceutical Company|Takeda]]. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained [[Food and Drug Administration|FDA]] approval. |
|||
==Pharmacology== |
|||
Mitiglinide is thought to stimulate [[insulin]] secretion by closing the ATP-sensitive potassium [[ATP-sensitive potassium channel|K<sub>ATP</sub> channels]] in pancreatic [[Beta cell|β cell]]s. |
|||
==Dosage== |
|||
Mitiglinide is delivered in tablet form. |
|||
== References == |
|||
{{reflist}} |
|||
== External links == |
|||
* [http://www.elixirpharm.com/ Elixir Pharmaceuticals] — website of the U.S. rights holder for mitiglinide. |
|||
{{Oral hypoglycemics}} |
|||
{{Ion channel modulators}} |
|||
[[Category:Carboxamides]] |
|||
[[Category:Isoindoles]] |
|||
[[Category:Meglitinides]] |
|||
[[Category:Potassium channel blockers]] |
|||
[[Category:Carboxylic acids]] |
|||